Prescribing Cyclic Antidepressants for Vitiligo Patients: Which Agents Are Superior, Which Are Not?

Namazi, Mohammad Reza

doi:10.1159/000073036

Cited by 17 publications

(21 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neuroendocrine dysregulation, which is responsible for the development of depression, has been implicated as one of the potential mechanisms for the depigmentation observed in vitiligo. In particular, increased levels of norepinephrine and acetylcholine have been postulated to play important roles . The onset of pigment loss was triggered by psychological stress in up to 62·5% of cases of vitiligo .…”

Section: Discussionmentioning

confidence: 99%

Vitiligo and depression: a systematic review and meta‐analysis of observational studies

et al. 2017

View full text Add to dashboard Cite

Vitiligo is a common depigmenting disorder with profound psychosocial impacts. Previous observational studies have suggested a link between vitiligo and psychiatric morbidity, such as depression. However, variability in study design makes it difficult to quantify accurately the relationship between vitiligo and depression. We aimed to investigate the underlying prevalence and risk of depression among patients with vitiligo. A comprehensive search of MEDLINE, Embase and the Cochrane Library was conducted. Cross-sectional, case-control or cohort studies that assessed the prevalence of depression among patients with vitiligo or the relationship between vitiligo and depression were included. DerSimonian and Laird random-effects models were utilized to calculate the pooled prevalence and relative risks. Publication bias was evaluated by funnel plots and Egger's tests. Twenty-five studies with 2708 cases of vitiligo were included. Based on diagnostic codes, the pooled prevalence of depression among patients with vitiligo was 0·253 [95% confidence interval (CI) 0·16-0·34; P < 0·001)]. Using self-reported questionnaires, the pooled prevalence of depressive symptoms was 0·336 (95% CI 0·25-0·42; P < 0·001). The pooled odds ratio of depression among patients with vitiligo was 5·05 vs. controls (95% CI 2·21-11·51; P < 0·001). Moderate-to-high heterogeneity was observed between the studies. Patients with vitiligo were significantly more likely to suffer from depression. Clinical depression or depressive symptoms can be prevalent, with the actual prevalence differing depending on screening instruments or, possibly, geographical regions. Clinicians should actively evaluate patients with vitiligo for signs/symptoms of depression and provide appropriate referrals to manage their psychiatric symptoms accordingly.

show abstract

Section: Discussionmentioning

confidence: 99%

Vitiligo and depression: a systematic review and meta‐analysis of observational studies

et al. 2017

View full text Add to dashboard Cite

show abstract

“…One of the potential mechanisms that might explain the depigmentation observed as part of the disorder's clinical presentation, is believed to have links to neuroendocrine dysregulation, a causal factor responsible for developing depression. It has widely been suggested that increased levels of norepinephrine and acetylcholine play a significant role [44] and the onset of pigment loss in 62-65% of the cases would be triggered by psychological stress [45]. As a response to psychic stress, through the activation of hypothalamic-pituitary-adrenal axis, catecholamine discharge occurs and by binding to alpha-receptors on dermal arterioles and activation, vasoconstruction, hypoxia, and production of excessive free oxygen radicals are triggered, resulting in destruction of melanocytes [46,47].…”

Section: Introductionmentioning

confidence: 99%

Quality of life, depression, and anxiety in Turkish children with vitiligo and their parents

Önen

Kundak

Erkuran

et al. 2018

Psychiatry and Clinical Psychopharmacology

View full text Add to dashboard Cite

“…SCF/c-kit signaling was evidenced to enable MAPK to phosphorylate the microphthalmia-associated transcription factor (Mitf) for accentuating melanocytic tyrosinase activity and viability (Hemesath et al, 1998;Hachiya et al, 2001). Clinical pathology of vitiligo vulgaris has indicated the deficiency of c-kit receptor (Norris et al, 1996;Namazi, 2003), which was proposed to be attenuated by abundance of NE (Imokawa, 2004). Despite controversy, the decrease in SCF expression was not observed in lesional vitiligo epidermis (Kitamura et al, 2004;Lee et al, 2005).…”

Section: Abbreviationsmentioning

confidence: 99%

Evidence that geniposide abrogates norepinephrine-induced hypopigmentation by the activation of GLP-1R-dependent c-kit receptor signaling in melanocyte

Lan¹,

Wang²,

Lan³

et al. 2008

Journal of Ethnopharmacology

View full text Add to dashboard Cite

Prescribing Cyclic Antidepressants for Vitiligo Patients: Which Agents Are Superior, Which Are Not?

Cited by 17 publications

References 3 publications

Vitiligo and depression: a systematic review and meta‐analysis of observational studies

Vitiligo and depression: a systematic review and meta‐analysis of observational studies

Quality of life, depression, and anxiety in Turkish children with vitiligo and their parents

Evidence that geniposide abrogates norepinephrine-induced hypopigmentation by the activation of GLP-1R-dependent c-kit receptor signaling in melanocyte

Contact Info

Product

Resources

About